Glycolysis and Gluconeogenesis: Carbon, Redox, and Clinical Decisions
Trace glucose through ATP production and glucose synthesis, then distinguish red-cell disease, fasting disorders, alcohol effects, and laboratory pitfalls.
A red cell needs glucose even when oxygen delivery is excellent. A fasting liver can make glucose while using fat for its own energy. Those facts fit together once you separate three questions: who needs ATP, who needs circulating glucose, and where the electrons can go? By the end, you should be able to trace carbon, count ATP and redox changes, and use a clinical trigger to identify the disrupted reaction.
Follow the carbon, then count the payments
Glycolysis occurs in the cytosol. One six-carbon glucose becomes two three-carbon pyruvates. The early reactions spend two ATP; the later reactions generate four ATP and two NADH. Net direct yield is two ATP per glucose. This calculation describes glycolysis itself, not the additional ATP obtained when mitochondrial pathways oxidize pyruvate and reoxidize NADH. Oxygen is not a glycolytic substrate, so the pathway can operate without it. Continued flux still requires a supply of oxidized NAD.
One glucose, followed through the two accounting phases
Invest: glucose → glucose 6-phosphate → fructose 6-phosphate → fructose 1,6-bisphosphate. Phosphoglucose isomerase catalyzes the middle rearrangement. Hexokinase or glucokinase spends one ATP; PFK-1 spends the other.
Split: aldolase produces glyceraldehyde 3-phosphate and dihydroxyacetone phosphate. Triose phosphate isomerase converts the latter into a second glyceraldehyde 3-phosphate.
Everything after the split occurs twice per original glucose. This is why two ATP-producing reactions give four ATP gross, and GAPDH gives two NADH; subtracting the two ATP invested leaves two ATP net. [1]
Glyceraldehyde 3-phosphate dehydrogenase, abbreviated GAPDH, incorporates inorganic phosphate while reducing NAD to NADH. Its product is 1,3-bisphosphoglycerate. Phosphoglycerate kinase then transfers a phosphate to ADP. Phosphoglycerate mutase relocates the remaining phosphate, enolase removes water, and pyruvate kinase transfers the phosphate from phosphoenolpyruvate to ADP. The two ATP-generating enzymes are phosphoglycerate kinase and pyruvate kinase. GAPDH generates the high-energy substrate for the first payment; it does not itself make ATP. [1]
The names bisphosphate and diphosphate are not interchangeable here: fructose 1,6-bisphosphate has phosphates attached at two different carbon positions. Fructose 2,6-bisphosphate is a separate regulatory molecule. It is not the six-carbon substrate cleaved by aldolase. Keeping those two molecules distinct prevents a regulation question from turning into an enzyme-name guessing exercise.
Trace one glucose with two tokens for the investment phase. After aldolase, duplicate every remaining carbon path. The visible consequence is that everything after the split occurs twice, producing four ATP gross but only two ATP net. Transfer this rule to an erythrocyte that converts both pyruvates to lactate.
Try it here · Checkpoint 1 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 28
Show answer and explanations for case 28
A. Two ATP and two lactates, with NAD recycled (Best answer)
Four ATP are generated after two are invested, and LDH recycles the two NADH.
Reasoning steps for option A
How much ATP does glycolysis make and spend per glucose?
It makes four ATP and spends two, for two ATP net.
What happens to NADH when both pyruvates become lactate?
LDH reoxidizes both NADH, recycling NAD.
How many lactates form?
Two, one from each three-carbon pyruvate.
B. Four ATP and two lactates, with NAD recycled (Why this does not fit)
Four is gross production and omits the two ATP investment.
Reasoning steps for option B
Why might four ATP seem the answer?
Glycolysis does make four ATP.
Why is four wrong for net yield?
Hexokinase and phosphofructokinase-1 each consume one ATP before any is made, so subtracting those two from the four produced leaves two.
C. Two ATP and one lactate, with NAD recycled (Why this does not fit)
One six-carbon glucose produces two three-carbon lactates.
Reasoning steps for option C
Why might one lactate seem right?
One glucose enters the pathway.
How many lactates does one glucose give?
Two, because the six-carbon sugar splits into two three-carbon units.
D. Two ATP and two lactates, with two NADH retained (Why this does not fit)
LDH consumes the glycolytic NADH when both pyruvates become lactate.
Reasoning steps for option D
Why might NADH seem to remain?
GAPDH makes two NADH per glucose.
What happens to that NADH here?
LDH uses it to reduce both pyruvates, leaving no net NADH.
Takeaway: Specify both the tissue and whether the accounting is gross or net.
The same glucose meets different tissue priorities
Hexokinase in many tissues has high affinity for glucose and is inhibited by glucose 6-phosphate. Glucokinase in hepatocytes and pancreatic β cells responds over a higher glucose range and is not inhibited directly by its glucose 6-phosphate product. In the liver, this favors glucose processing after meals; in β cells, glucose metabolism contributes to glucose sensing. Neither enzyme commits glucose exclusively to glycolysis: glucose 6-phosphate can also enter glycogen metabolism or the pentose phosphate pathway. [19]
PFK-1 makes the committed glycolytic intermediate fructose 1,6-bisphosphate. AMP and fructose 2,6-bisphosphate favor its activity; abundant ATP and citrate oppose it. The regulatory meaning matters more than memorizing a list: low cellular energy favors ATP production, while a plentiful energy supply reduces the need to consume another glucose molecule. Muscle acidity also restrains PFK-1 during intense exertion.
Fed liver: insulin favors the hepatic PFK-2 activity of the bifunctional PFK-2/FBPase-2 protein. Fructose 2,6-bisphosphate rises, promoting PFK-1 and inhibiting fructose 1,6-bisphosphatase.
Fasting liver: glucagon signaling through cAMP and protein kinase A favors hepatic FBPase-2 activity. Fructose 2,6-bisphosphate falls, allowing gluconeogenesis to predominate. Phosphorylation also inhibits liver pyruvate kinase.
Working muscle:local ATP demand, AMP, calcium-linked signaling and substrate supply guide fuel use. A hepatic glucagon diagram cannot be copied onto every muscle isoenzyme.
Predict the direction of hepatic glycolysis and gluconeogenesis from hormonal state. [1][2]
Fructose 1,6-bisphosphate activates pyruvate kinase by feed-forward regulation, helping match the pathway's late capacity to its early flux. ATP and alanine restrain pyruvate kinase. Do not translate this into “phosphorylation activates catabolism”: hepatic pyruvate kinase is a direct counterexample. Cortisol and growth hormone also cannot be substituted for glucagon in a cAMP diagram; their receptor signaling and time courses differ. [1]
Compare a fed hepatocyte with a fasting hepatocyte before naming an enzyme. Raising fructose 2,6-bisphosphate favors PFK-1, whereas lowering it releases fructose 1,6-bisphosphatase from inhibition. Now predict what hepatic glucagon does to pyruvate kinase at the same time.
NAD recycling explains lactate and red-cell vulnerability
GAPDH stops if NAD becomes unavailable. Lactate dehydrogenase reduces pyruvate to lactate and reoxidizes NADH, sustaining glycolysis. This reaction adds no ATP. In a mature erythrocyte, the absence of mitochondria makes glycolytic substrate-level phosphorylation essential even in oxygenated arterial blood. In muscle, lactate formation can increase when glycolytic flux exceeds mitochondrial oxidation capacity; its presence is not proof that the entire tissue contains no oxygen.
Lactate is usable carbon. Other tissues can oxidize it, and the liver and kidney can return its carbon to glucose. In the Cori cycle, peripheral glycolysis gains two ATP while hepatic synthesis of glucose from two lactates spends six high-energy phosphate equivalents. The body transfers an energy burden between tissues; it does not create free energy. Alanine provides a second connection: muscle transfers an amino group onto pyruvate, exporting both carbon and nitrogen for hepatic handling. [2]
The erythrocyte has a tradeoff at 1,3-bisphosphoglycerate. The Rapoport-Luebering pathway produces 2,3-bisphosphoglycerate, which favors oxygen release from adult hemoglobin. Returning through 3-phosphoglycerate bypasses the phosphoglycerate kinase ATP payment. Fetal hemoglobin binds 2,3-BPG less strongly, contributing to its higher oxygen affinity. [20] Increased 2,3-BPG can partly support oxygen delivery in chronic anemia; it cannot restore the missing hemoglobin mass.
Connect red-cell ATP dependence, NAD recycling, and the oxygen-affinity tradeoff. [1][3][18][20]
PKLR-related pyruvate kinase deficiency impairs red-cell ATP supply, membrane maintenance and survival. Expect congenital or chronic hemolysis with variable severity, rather than a literal absence of every ATP molecule. Mitapivat, an oral allosteric activator of red-cell pyruvate kinase, was approved in the United States in 2022 for hemolytic anemia in adults with pyruvate kinase deficiency. [25] PFKM-related disease can combine exertional muscle symptoms with hemolysis. [24] By comparison, the pentose phosphate pathway provides NADPH for antioxidant defense, not the NADH used in glycolytic energy accounting.
An oxidant-triggered hemolytic pattern points toward impaired antioxidant protection, while lifelong nonspherocytic hemolysis warrants evaluation of erythrocyte enzymes and other inherited causes. A negative direct antiglobulin test supports this direction but does not identify a particular enzyme. [3][4]
Stored erythrocytes lose 2,3-BPG, but an affinity change alone does not establish a worse clinical outcome for every recipient. Randomized evidence did not show a survival advantage from routinely using fresher rather than standard-issue red cells in critically ill adults. Product handling and licensed rejuvenation processes are transfusion-service decisions, not a universal “add inosine and extend the expiration” rule. [12]
In G6PD deficiency, reduced pentose phosphate NADPH availability compromises glutathione recycling and oxidant protection. Infections, certain drugs or fava beans can precipitate hemolysis; the exposure and red-cell findings matter. This is a distinct problem from the ATP shortage of pyruvate kinase deficiency, although both disorders may shorten red-cell survival. [18]
Follow 1,3-bisphosphoglycerate through either phosphoglycerate kinase or the erythrocyte branch. Choosing the 2,3-BPG route sacrifices one ATP opportunity while favoring oxygen release from adult hemoglobin. Apply the tradeoff to chronic anemia without claiming that it restores missing hemoglobin.
Try it here · Checkpoint 2 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 12
Show answer and explanations for case 12
A. Bypassing an ATP payment at phosphoglycerate kinase (Best answer)
The branch rejoins at 3-phosphoglycerate and sacrifices this direct ATP opportunity.
Reasoning steps for option A
Where does the 2,3-BPG branch start and rejoin?
It starts at 1,3-bisphosphoglycerate and rejoins at 3-phosphoglycerate.
Which ATP step does this route skip?
The phosphoglycerate kinase reaction, so that ATP is not made.
How does this fit the patient?
More 2,3-BPG right-shifts the curve at a small cost in ATP per glucose.
B. Bypassing the pyruvate kinase ATP payment (Why this does not fit)
The 2,3-BPG route rejoins before pyruvate kinase and specifically bypasses phosphoglycerate kinase.
Reasoning steps for option B
Why might pyruvate kinase seem to be the missed payment?
Pyruvate kinase is the other ATP-producing step.
Why is it still collected?
The branch rejoins at 3-phosphoglycerate, before pyruvate kinase.
C. Consumption of NADPH during the BPG-mutase reaction (Why this does not fit)
The defining energetic tradeoff is the missed substrate-level ATP reaction, not NADPH consumption.
Reasoning steps for option C
Why might NADPH seem involved in red-cell metabolism?
Red cells depend on NADPH for antioxidant defense.
Does BPG mutase consume NADPH?
No; the cost is a missed ATP-producing step.
D. Higher hemoglobin affinity with reduced peripheral oxygen release (Why this does not fit)
Increased 2,3-BPG favors oxygen release by lowering adult hemoglobin affinity.
Reasoning steps for option D
Why might an affinity change be the expected answer?
2,3-BPG does change hemoglobin oxygen affinity.
Why is the direction of that affinity change wrong?
2,3-BPG lowers affinity and increases release, matching the right shift.
Takeaway: Red cells trade some ATP yield for modulation of oxygen affinity.
Gluconeogenesis needs bypasses and an energy source
Glucose synthesis is not glycolysis read backward. Hexokinase, PFK-1 and pyruvate kinase operate far from equilibrium in their usual cellular settings. Four enzymes bypass those three reactions: pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose 1,6-bisphosphatase and glucose 6-phosphatase. Starting with two pyruvates costs four ATP, two GTP and two NADH. The ATP and GTP together represent six high-energy phosphate equivalents.
The compartment map for making blood glucose
Mitochondrial matrix: biotin-dependent pyruvate carboxylase uses ATP and bicarbonate to form oxaloacetate. Acetyl-CoA activates it.
Across the inner membrane: oxaloacetate cannot simply diffuse out. Carbon can travel through malate, aspartate or phosphoenolpyruvate routes according to cellular conditions and enzyme distribution.
Cytosolic reactions: PEPCK consumes GTP in the oxaloacetate-to-PEP reaction; fructose 1,6-bisphosphatase bypasses PFK-1. PEPCK also has a mitochondrial isoform.
Endoplasmic reticulum: the glucose 6-phosphatase system permits release of free glucose in glucose-producing organs.
Malate dehydrogenase interconverts malate and oxaloacetate. Aspartate aminotransferase transfers an amino group between aspartate and α-ketoglutarate, yielding oxaloacetate and glutamate in one direction. It does not interconvert malate and an amino acid. [2]
Liver and renal cortex both contribute to systemic gluconeogenesis, with proportions changing during fasting and acid-base disturbances. Skeletal muscle lacks the glucose 6-phosphatase capacity needed for substantial export of free glucose. The adrenal cortex is not the standard second glucose-producing organ. Glycogen use, gluconeogenesis, lipolysis and ketogenesis overlap during fasting; they do not begin at rigid successive hour marks. Brain ketone use increases with adaptation while red cells continue to require glucose. [2]
Lactate, alanine and glycerol provide gluconeogenic carbon. Glycerol enters at the triose phosphate level and does not require the pyruvate-to-PEP bypass. Even-carbon fatty acids provide ATP and acetyl-CoA to support the process but do not provide net glucose carbon in humans. Pyruvate dehydrogenase is irreversible, and the TCA cycle does not create a net gain of oxaloacetate from acetyl-CoA. The glycerol backbone of a triglyceride is therefore metabolically different from its even-carbon fatty acids.
Sort lactate, alanine, glycerol, and palmitate by their first gluconeogenic entry point. Glycerol enters at the triose level, while even-carbon fatty acids provide energy but no net glucose carbon. Use the same routing rule to explain why two pyruvates require four bypass enzymes.
Use the trigger to identify the disrupted reaction
A fasting child with hypoglycemia, hepatomegaly and elevated lactate raises concern for glycogen storage disease I: both glycogen-derived and newly synthesized glucose encounter the impaired final glucose 6-phosphatase system. G6PC1 affects the catalytic enzyme; SLC37A4 affects the transporter. A child who becomes ill after fruit, sucrose or sorbitol instead suggests hereditary fructose intolerance.
Aldolase B deficiency traps phosphate in fructose 1-phosphate and compromises energy-dependent glucose production. Avoid a diagnostic fructose challenge; biochemical and molecular evaluation are safer. Fasting hypoglycemia with lactic acidosis can also reflect fructose 1,6-bisphosphatase deficiency. The trigger, organ findings and confirmatory testing separate these overlapping biochemical consequences. [5][6][14]
Ethanol oxidation increases the hepatic NADH-to-NAD ratio. [22] Lactate formation and oxaloacetate reduction are favored, making gluconeogenesis difficult when glycogen is depleted. In a malnourished person with symptomatic hypoglycemia, give glucose promptly and provide thiamine when indicated; do not postpone rescue glucose to enforce a vitamin-first sequence. Thiamine supports pyruvate dehydrogenase and other reactions, while niacin provides precursors for NAD and NADP. Photosensitive dermatitis, diarrhea and neuropsychiatric changes suggest pellagra; deficient intake or impaired tryptophan availability can contribute. [7][11][13]
Separate laboratory chemistry from bedside diagnosis. Fluoride inhibits enolase, but fluoride alone does not immediately prevent the early fall in glucose in an unseparated blood sample. Prompt processing or an appropriate rapidly effective glycolysis-inhibiting collection system is needed. [8]Arsenate can uncouple the GAPDH/phosphoglycerate kinase energy-conserving sequence experimentally; [21] arsenite inhibits lipoate-dependent complexes. [15] A history of mercury exposure does not establish a selective clinical GAPDH defect. Toxic exposures require exposure-specific assessment, not an enzyme mnemonic used as a diagnostic test.
Glucose uptake on FDG PET reflects transport and phosphorylation of a glucose analogue; increased uptake also occurs in inflammation. [16] Aerobic glycolysis in cancer supports biosynthesis and redox needs as well as ATP production. It does not mean all tumors have nonfunctional mitochondria or one identical PKM2 state. Metformin reduces hepatic glucose production, but presenting one proposed molecular target as its exclusive mechanism overstates the evidence. [9] Valproate-associated confusion warrants consideration of hyperammonemia even when liver tests are normal, not an assumed selective PEPCK inhibition. [10] Do not infer a glucose-infusion indication from myocardial fuel biochemistry alone.
NICE distinguishes monitored treatment of hyperglycemia in acute coronary syndromes from routine intensive insulin/glucose therapy, which it does not recommend unless clinically indicated. [23]
Hartnup disease impairs transport of neutral amino acids in intestine and kidney, including tryptophan. Reduced precursor availability can produce pellagra-like episodes during nutritional stress, with aminoaciduria distinguishing the transport problem from low niacin intake alone. The biochemical connection is impaired support for niacin-derived cofactors, not a mutation of GAPDH itself. [17]
Start with the trigger before selecting an enzyme: fruit exposure, fasting, ethanol, oxidant stress, or delayed specimen processing. The trigger plus the organ pattern separates phosphate trapping, a blocked glucose exit, a redox shift, antioxidant failure, and continued ex vivo glycolysis. Apply the comparison to a new patient before reading the choices.
Try it here · Checkpoint 3 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 6
Show answer and explanations for case 6
A. Fructose 1-phosphate rises as free phosphate falls (Best answer)
Aldolase B deficiency traps dietary fructose as fructose 1-phosphate, depleting free phosphate and ATP while impairing glycogenolysis and gluconeogenesis.
Reasoning steps for option A
What does illness after pear puree but not formula suggest?
A fructose-triggered disorder, since pears contain fructose and sorbitol.
What does aldolase B deficiency do to fructose 1-phosphate?
It traps dietary fructose as fructose 1-phosphate, which accumulates.
How does that explain low phosphate and glucose?
Trapped phosphate depletes free phosphate and ATP, impairing glycogenolysis and gluconeogenesis.
B. Fructose 6-phosphate rises as ATP production increases (Why this does not fit)
This does not describe phosphate trapping and would not account for hypophosphatemia after fructose exposure.
Reasoning steps for option B
Why might a hexose phosphate rise seem plausible after fruit?
Fructose enters sugar-phosphate metabolism, so a fructose phosphate rise sounds relevant.
Why is this pattern wrong?
It does not trap phosphate and would not cause hypophosphatemia or reduced energy.
C. Galactose 1-phosphate rises while phosphate remains available (Why this does not fit)
Galactose 1-phosphate accumulation follows galactose exposure, not the fruit-triggered fructose pattern, and it does not match the stated phosphate depletion.
Reasoning steps for option C
Why could galactose metabolism be considered in an infant with liver disease?
Galactosemia also causes vomiting, hepatomegaly, and hypoglycemia in infants.
Which detail excludes galactosemia here?
The infant tolerates milk formula, and symptoms follow fructose-containing fruit.
D. Sorbitol accumulates in the lens while blood glucose rises (Why this does not fit)
Sorbitol accumulation is associated with hyperglycemic tissue injury, not acute fructose-triggered hypoglycemia and hepatic phosphate trapping.
Reasoning steps for option D
Why might sorbitol be linked to pear puree?
Pears contain sorbitol, which is converted to fructose.
Why does lens sorbitol accumulation not fit?
It is a chronic hyperglycemic complication, whereas this infant has acute hypoglycemia.
Takeaway: Hereditary fructose intolerance causes fructose 1-phosphate trapping, phosphate depletion, and secondary inhibition of hepatic glucose release after fructose exposure.
These original educational scenarios ask you to identify the reaction, tissue priority or management distinction. Each answer includes a reason for accepting or rejecting every option.
Case 1
Show answer and explanations for case 1
A. Decreased ATP with increased 2,3-BPG (Best answer)
Pyruvate kinase deficiency removes a glycolytic ATP-producing step in mitochondria-free erythrocytes, while upstream carbon can be diverted toward 2,3-BPG.
Reasoning steps for option A
What does lifelong DAT-negative hemolysis with low pyruvate kinase activity point to?
Pyruvate kinase deficiency, an inherited defect in the last glycolytic ATP-producing step.
Why does ATP fall in these red cells?
Mature erythrocytes lack mitochondria, so losing the pyruvate kinase payment removes a major ATP source.
Why does 2,3-BPG rise at the same time?
Glycolytic intermediates back up above the block and more carbon is diverted through the 2,3-BPG branch.
B. Decreased NADPH with increased Heinz-body formation (Why this does not fit)
This is the antioxidant pattern expected with G6PD deficiency, but G6PD activity, glutathione reduction, and the absence of oxidant-linked episodes argue against it.
Reasoning steps for option B
Why is an NADPH defect tempting in a child with hemolysis?
G6PD deficiency is the most familiar enzyme cause of nonimmune hemolysis.
Which findings exclude the antioxidant pattern?
G6PD activity and glutathione reduction are normal and episodes are not oxidant-linked.
C. Increased ATP with decreased lactate production (Why this does not fit)
Reduced pyruvate kinase can lower downstream pyruvate and lactate, but it cannot increase ATP because the blocked step normally produces ATP.
A pyruvate kinase block reduces pyruvate available for lactate formation.
Why can ATP not rise?
The blocked enzyme normally makes ATP, so its loss lowers rather than raises ATP.
D. Increased mitochondrial ATP with decreased reticulocytosis (Why this does not fit)
Mature erythrocytes have no mitochondria, and ongoing hemolysis raises rather than lowers the reticulocyte response.
Reasoning steps for option D
Why might a cell compensate with oxidative ATP?
Most cells can shift to mitochondrial ATP when glycolysis falters.
Why is that impossible here, and what happens to reticulocytes?
Mature red cells have no mitochondria, and ongoing hemolysis raises the reticulocyte count.
Takeaway: Pyruvate kinase deficiency limits erythrocyte ATP and can increase upstream 2,3-BPG; normal antioxidant testing separates it from G6PD deficiency.
A. Pyruvate reduction to lactate (Why this does not fit)
An isolated lactate dehydrogenase defect could blunt lactate formation but would not explain the combined glycogen-rich myopathy and chronic erythrocyte hemolysis.
Reasoning steps for option A
Why is a lactate-forming defect tempting with a flat forearm lactate?
The failed lactate rise could suggest lactate dehydrogenase is the missing step.
Which findings does an isolated LDH defect fail to explain?
Glycogen accumulation in muscle together with chronic erythrocyte hemolysis.
B. Fructose 1-phosphate cleavage (Why this does not fit)
Aldolase B deficiency produces fructose-triggered hepatic illness rather than an exertional muscle plus erythrocyte phenotype.
Reasoning steps for option B
Why might a fructose-cleaving defect come up in a glycolysis question?
Aldolase B deficiency is a classic inherited carbohydrate disorder.
Why does it not fit this patient?
It causes fructose-triggered liver illness, not exertional myopathy with hemolysis.
C. Fructose 6-phosphate phosphorylation (Best answer)
Muscle PFK deficiency blocks the PFK-1 step, explaining low exercise lactate, glycogen accumulation, exertional symptoms, and hemolysis in erythrocytes that express the muscle isoform.
Reasoning steps for option C
What do early cramps, myoglobinuria, and no lactate rise indicate?
Muscle cannot run glycolysis from glycogen during intense exercise.
Why does glycogen accumulate?
A block at PFK-1 traps upstream sugar phosphates, so glycogen builds up.
Why is there also hemolysis?
Red cells express the muscle PFK subunit, so the same PFKM defect shortens their survival.
D. Glucose 6-phosphate hydrolysis (Why this does not fit)
The glucose 6-phosphatase system supports hepatic and renal glucose export; its failure causes fasting metabolic disease, not this muscle and erythrocyte combination.
Reasoning steps for option D
Why might a glucose 6-phosphate step be considered with excess glycogen?
Glycogen storage disease I is a well-known cause of glycogen accumulation.
Why does the glucose 6-phosphatase system not fit?
Its failure causes fasting hypoglycemia with liver enlargement, not exercise-induced muscle symptoms.
Takeaway: Exercise intolerance with a blunted lactate rise plus chronic hemolysis localizes the defect to muscle PFK and its fructose 6-phosphate phosphorylation step.
A. Blocked hydrolysis of glucose 6-phosphate (Best answer)
Glycogenolysis and gluconeogenesis both converge on glucose 6-phosphate, so failure of its final hydrolysis prevents glucose export and diverts accumulated carbon toward lactate and lipid.
Reasoning steps for option A
Why does glucagon fail to raise glucose in this infant?
Glycogen breaks down to glucose 6-phosphate but cannot be released as free glucose.
Why does lactate rise further during the challenge?
The trapped glucose 6-phosphate is diverted into glycolysis, producing more lactate.
Which bottleneck explains both findings?
Blocked hydrolysis of glucose 6-phosphate, the shared exit for glycogenolysis and gluconeogenesis.
B. Failure to release glucose 1-phosphate from glycogen (Why this does not fit)
A glycogen-phosphorylase problem would impair glycogenolysis but would not also block glucose made through gluconeogenesis at their shared final exit.
Reasoning steps for option B
Why might a glycogen-release defect explain a poor glucagon response?
Phosphorylase defects also blunt glycogen breakdown.
Which feature separates this from a phosphorylase problem?
Glucose made by gluconeogenesis also fails to reach blood, pointing to their shared final step.
C. Failure to convert pyruvate to oxaloacetate (Why this does not fit)
Pyruvate carboxylase failure impairs gluconeogenesis but does not explain why glucagon-driven glycogen breakdown also fails to release free glucose.
Reasoning steps for option C
Why might pyruvate carboxylase be considered in fasting hypoglycemia with lactic acidemia?
Its failure impairs gluconeogenesis and raises lactate.
Why does it fail to explain the glucagon result?
Pyruvate carboxylase deficiency does not stop glucagon-driven glycogen breakdown from releasing glucose.
D. Failure to phosphorylate fructose after meals (Why this does not fit)
Fructokinase deficiency is generally benign and cannot explain severe fasting disease, lactic acidemia, or the failed glucagon response.
Reasoning steps for option D
Why could a fructose-handling defect enter the differential?
Fructose metabolism disorders affect the liver in infancy.
Why is fructokinase deficiency wrong?
It is benign and causes no fasting hypoglycemia, lactic acidemia, or failed glucagon response.
Takeaway: Glycogen storage disease I blocks the final glucose 6-phosphate exit shared by glycogenolysis and gluconeogenesis, so glucagon cannot restore blood glucose.
A. Fructose 1,6-bisphosphate hydrolysis (Best answer)
Preserved early glycogen mobilization with later failure of glucose synthesis points to fructose 1,6-bisphosphatase, which bypasses PFK-1 during gluconeogenesis.
Reasoning steps for option A
What does an early glucose rise with glucagon show?
Glycogen breakdown and the final glucose exit are intact.
What happens after glycogen is gone?
Glucose falls while lactate rises, so the problem is making new glucose.
Which gluconeogenic enzyme fits that pattern?
Fructose 1,6-bisphosphatase, the bypass for PFK-1.
B. Fructose 6-phosphate phosphorylation (Why this does not fit)
PFK-1 deficiency impairs glycolysis and produces an exertional muscle phenotype rather than isolated late-fasting gluconeogenic failure.
Reasoning steps for option B
Why might PFK-1 seem linked to this fructose-phosphate step?
PFK-1 acts at the same fructose phosphate point in the opposite direction.
Why is a PFK-1 defect wrong?
It impairs glycolysis and causes exercise intolerance, not late-fasting hypoglycemia.
C. Glycerol phosphorylation (Why this does not fit)
Loss of glycerol kinase affects one precursor route but would not explain broad failure to use lactate and other pyruvate-derived substrates after glycogen depletion.
Reasoning steps for option C
Why could glycerol phosphorylation be relevant to fasting glucose?
Glycerol is a gluconeogenic precursor during fasting.
Why is glycerol kinase deficiency too narrow?
It blocks only glycerol entry, not the use of lactate and other pyruvate-derived substrates.
D. Pyruvate oxidation to acetyl-CoA (Why this does not fit)
Pyruvate dehydrogenase directs carbon into oxidation, not the gluconeogenic bypass needed to convert fasting lactate into glucose.
Reasoning steps for option D
Why might pyruvate dehydrogenase be considered with lactic acidosis?
PDH deficiency also raises lactate.
Why does PDH not explain the hypoglycemia?
PDH sends pyruvate toward oxidation, not toward glucose synthesis.
Takeaway: A normal early glycogen response followed by hypoglycemia and lactic acidosis after glycogen depletion localizes disease to fructose 1,6-bisphosphatase.
A. Higher insulin-release threshold and reduced hepatic glucose trapping (Best answer)
Reduced glucokinase activity raises the pancreatic β-cell threshold for glucose-stimulated insulin release and decreases hepatic phosphorylation and trapping of glucose.
Reasoning steps for option A
What does a stable, mild, multigenerational fasting hyperglycemia suggest?
A dominant glucokinase variant causing mild lifelong hyperglycemia.
How does reduced glucokinase affect the β cell?
It raises the glucose threshold for insulin release.
How does it affect the liver?
Hepatocytes phosphorylate and trap less glucose after meals.
B. Lower insulin-release threshold and increased hepatic glucose trapping (Why this does not fit)
These changes would favor lower fasting glucose rather than stable lifelong mild hyperglycemia.
Reasoning steps for option B
Why does this pairing seem to involve the right enzyme functions?
It names the β-cell threshold and hepatic trapping, the two roles of glucokinase.
Why is the direction wrong?
A lower threshold and more trapping would lower fasting glucose, not raise it.
C. Loss of skeletal-muscle GLUT4 and excessive hepatic glycogen synthesis (Why this does not fit)
Marked peripheral insulin resistance usually raises fasting insulin and produces a larger metabolic syndrome phenotype, neither of which is supplied here.
Reasoning steps for option C
Why might insulin resistance be considered for high fasting glucose?
Insulin resistance is the most common cause of hyperglycemia.
Which findings argue against insulin resistance?
The patient is lean and fasting insulin is not elevated.
D. Impaired erythrocyte glycolysis and reduced pancreatic glucagon release (Why this does not fit)
Erythrocyte glycolysis does not set the fasting glucose threshold, and reduced glucagon cannot explain this dominant multigenerational pattern.
Reasoning steps for option D
Why might a red-cell or glucagon change seem relevant to glucose?
Red cells consume glucose and glucagon raises it.
Why does this pairing fail?
Red-cell glycolysis does not set fasting glucose, and less glucagon would lower glucose.
Takeaway: Glucokinase-related mild hyperglycemia reflects a higher β-cell glucose-sensing threshold plus reduced hepatic glucose phosphorylation, not severe insulin resistance.
A. Pyruvate dehydrogenase and thiamine pyrophosphate (Best answer)
The tracer reaches pyruvate but not acetyl-CoA, localizing the block to pyruvate dehydrogenase; thiamine pyrophosphate is one of its required cofactors.
Reasoning steps for option A
Where does the labeled carbon stop?
It reaches pyruvate normally but forms little acetyl-CoA.
Which enzyme converts pyruvate to acetyl-CoA?
Pyruvate dehydrogenase, which requires thiamine pyrophosphate.
How do the clinical findings fit?
Malnutrition, confusion, and ataxia suggest thiamine deficiency, with pyruvate and lactate backing up.
B. PFK-1 and biotin (Why this does not fit)
A PFK-1 block would reduce formation of pyruvate from glucose, contradicting normal labeled pyruvate production, and PFK-1 does not use biotin.
Reasoning steps for option B
Why might PFK-1 seem responsible for impaired glucose metabolism?
It is the committed glycolytic step.
Which tracer result excludes PFK-1?
Labeled pyruvate forms normally, so glycolysis through PFK-1 is intact; PFK-1 also does not use biotin.
C. Lactate dehydrogenase and flavin adenine dinucleotide (Why this does not fit)
Lactate dehydrogenase uses NADH rather than FAD, and its failure would not specifically block labeled pyruvate from becoming acetyl-CoA.
Reasoning steps for option C
Why might LDH be suspected with high lactate?
LDH converts pyruvate to lactate.
Why does LDH not explain the block?
It uses NADH, not FAD, and its failure would not stop pyruvate becoming acetyl-CoA.
D. Pyruvate kinase and pyridoxal phosphate (Why this does not fit)
Pyruvate kinase acts before the normally formed labeled pyruvate and does not require pyridoxal phosphate.
Reasoning steps for option D
Why might pyruvate kinase be considered in a pyruvate question?
Pyruvate kinase is the enzyme that makes pyruvate.
Why is pyruvate kinase not the site?
Labeled pyruvate forms normally, so the step that makes it works; it also does not use pyridoxal phosphate.
Takeaway: Normal glycolytic pyruvate formation with reduced acetyl-CoA labeling localizes the defect to thiamine-dependent pyruvate dehydrogenase beyond glycolysis.
A. Glycerol 3-phosphate oxidation to DHAP (Best answer)
After glycerol kinase forms glycerol 3-phosphate, its oxidation produces DHAP, allowing glycerol carbon to enter at the triose-phosphate level without pyruvate carboxylase.
Reasoning steps for option A
What does glycerol kinase make from glycerol?
Glycerol 3-phosphate.
Which reaction comes next?
Glycerol 3-phosphate is oxidized to DHAP, a triose phosphate.
Why does this carbon avoid pyruvate?
DHAP enters gluconeogenesis above the pyruvate carboxylase and PEPCK bypasses.
B. Pyruvate carboxylation to oxaloacetate (Why this does not fit)
The tracer specifically bypasses pyruvate, so entry through pyruvate carboxylase contradicts the supplied labeling pattern.
Reasoning steps for option B
Why might pyruvate carboxylase seem to be the entry point?
Most gluconeogenic carbon enters through pyruvate carboxylase.
Which tracer result excludes this route?
The label reaches glucose without first appearing in pyruvate.
C. Acetyl-CoA condensation with oxaloacetate (Why this does not fit)
Citrate formation supports oxidation and biosynthesis but does not provide a net route from glycerol carbon into glucose.
Reasoning steps for option C
Why might citrate formation seem to route carbon into glucose?
It is the entry point of the TCA cycle, which feeds oxaloacetate.
Why is citrate synthase wrong here?
Acetyl-CoA condensation gives no net glucose carbon and is not where glycerol enters.
D. Glucose 6-phosphate hydrolysis in muscle (Why this does not fit)
Skeletal muscle does not substantially export free glucose, and this late reaction does not explain glycerol's initial triose-level entry.
Reasoning steps for option D
Why might glucose 6-phosphate hydrolysis seem to be the final step?
It is the last reaction before glucose release.
Why is this choice wrong?
Muscle does not export much glucose, and a late step does not explain glycerol's triose entry.
Takeaway: Glycerol enters gluconeogenesis as DHAP after glycerol phosphorylation and glycerol 3-phosphate oxidation, bypassing pyruvate carboxylase.
A. Less alanine export and less carbon for hepatic glucose (Best answer)
Blocking muscle alanine aminotransferase reduces transfer of both the amino group and pyruvate-derived carbon as alanine, limiting that substrate contribution to hepatic gluconeogenesis.
Reasoning steps for option A
What does muscle alanine aminotransferase do?
It transfers amino groups to pyruvate, forming alanine for export.
What happens when it is inhibited?
Less alanine leaves muscle, so less carbon reaches the liver for glucose.
B. More alanine export and greater nitrogen delivery without carbon (Why this does not fit)
Alanine formation requires the inhibited transamination, and alanine always carries a carbon skeleton together with its amino group.
Reasoning steps for option B
Why might more nitrogen export seem possible?
Muscle still has amino groups to dispose of.
Why is this impossible here?
Alanine formation needs the inhibited enzyme, and alanine always carries carbon with nitrogen.
C. Unchanged alanine export because albumin carries the amino group (Why this does not fit)
Albumin transports fatty acids and proteins but does not replace alanine as the coupled nitrogen and carbon carrier in this cycle.
Reasoning steps for option C
Why might albumin seem to carry nitrogen?
Albumin is a major plasma transport protein.
Why can albumin not replace alanine?
It does not carry amino groups as a coupled carbon and nitrogen carrier.
D. Less fatty-acid oxidation because alanine supplies acetyl-CoA (Why this does not fit)
Alanine contributes pyruvate-derived gluconeogenic carbon; it is not the required fuel that permits muscle fatty-acid oxidation during fasting.
Reasoning steps for option D
Why might alanine seem needed for fat oxidation?
Alanine and fatty acids both fuel fasting metabolism.
What is alanine's actual role?
It supplies pyruvate-derived carbon for liver glucose, not fuel for fat oxidation.
Takeaway: The glucose-alanine cycle couples muscle nitrogen disposal to delivery of pyruvate-derived carbon for hepatic glucose production.
A. FDG uptake directly measures complete glucose oxidation to carbon dioxide (Why this does not fit)
The measured retention reflects uptake and phosphorylation rather than completion of glucose oxidation.
Reasoning steps for option A
Why might FDG seem to measure full glucose oxidation?
FDG is a glucose analogue used to assess metabolism.
What does FDG retention actually reflect?
Transport and phosphorylation, which trap FDG as FDG 6-phosphate.
B. Postoperative FDG uptake by itself establishes recurrent malignancy (Why this does not fit)
Healing and inflammation can also produce uptake in the stated setting.
Reasoning steps for option B
Why might wound uptake suggest recurrent tumor?
The patient had surgery, and tumor recurrence is a concern.
What else causes uptake in a postoperative wound?
Healing and inflammation also produce FDG uptake.
C. Activated inflammatory tissues can also transport and phosphorylate FDG (Best answer)
The tracer signal is not specific to malignant cells and needs anatomical and clinical interpretation.
Reasoning steps for option C
Which cells in a wound take up FDG?
Activated inflammatory cells, which increase glucose transport and phosphorylation.
Why does that limit FDG as proof of cancer?
Tumor and inflamed tissue trap FDG by the same route, so uptake at both sites cannot by itself tell them apart; the lesion's anatomy and the clinical history must decide.
D. The intensity of uptake alone distinguishes infection from sterile inflammation (Why this does not fit)
Both may be FDG-avid; uptake alone does not establish their cause.
Reasoning steps for option D
Why might intensity seem to separate infection from sterile inflammation?
Stronger uptake can seem to indicate a more active process.
Why can intensity not decide the cause?
Both infection and sterile inflammation can be strongly FDG avid.
Takeaway: Metabolic avidity must be interpreted with anatomy and clinical context.
It hydrolyzes spontaneously to 3-phosphoglycerate.
Which ATP payment is lost?
The phosphoglycerate kinase ATP, since its substrate never forms.
C. Failure to form NADH at any glycolytic reaction (Why this does not fit)
The scenario describes lost phosphate-energy conservation, not necessarily loss of the GAPDH redox reaction.
Reasoning steps for option C
Why might NADH production seem affected?
Arsenate acts at the NADH-producing enzyme.
Does NADH still form?
Yes; the stem says NADH forms, and only phosphate-energy conservation is lost.
D. An extra substrate-level ATP payment at phosphoglycerate mutase (Why this does not fit)
Phosphoglycerate mutase relocates phosphate and does not supply a compensating ATP payment.
Reasoning steps for option D
Why might a phosphate shift seem to compensate?
Phosphoglycerate mutase moves a phosphate group.
Does phosphoglycerate mutase make ATP?
No; it only relocates the phosphate.
Takeaway: Arsenate replaces phosphate at GAPDH, so 1-arseno-3-phosphoglycerate hydrolyzes and the phosphoglycerate kinase ATP is lost while NADH still forms.
A. Nicotinamide replacement because tryptophan can supply niacin (Best answer)
Hartnup disease reduces neutral amino acid absorption and renal reuptake; loss of tryptophan can limit endogenous niacin synthesis, so nicotinamide can treat pellagra-like episodes.
Reasoning steps for option A
What does neutral aminoaciduria with pellagra-like episodes indicate?
Hartnup disease, with loss of tryptophan in intestine and kidney.
What does tryptophan supply?
It is a precursor for niacin synthesis.
Which treatment fits?
Nicotinamide, which replaces niacin for NAD.
B. Thiamine replacement because tryptophan supplies TPP (Why this does not fit)
Tryptophan is not a precursor for thiamine pyrophosphate, and thiamine deficiency does not explain neutral aminoaciduria.
Reasoning steps for option B
Why might thiamine be considered with ataxia?
Thiamine deficiency causes ataxia.
Why is thiamine wrong?
Tryptophan does not make thiamine, and thiamine deficiency does not cause aminoaciduria.
C. Riboflavin replacement because tryptophan supplies FAD (Why this does not fit)
Tryptophan does not supply riboflavin or FAD, and this choice fails to connect the amino acid transport defect to the pellagra-like skin and neurologic findings.
Reasoning steps for option C
Why might riboflavin be considered with skin changes?
Riboflavin deficiency causes skin and mucosal changes.
Why is riboflavin wrong?
Tryptophan does not make riboflavin or FAD.
D. Pantothenate replacement because tryptophan supplies coenzyme A (Why this does not fit)
Tryptophan is not the precursor for pantothenate or coenzyme A, so this does not explain the dietary sensitivity and neutral aminoaciduria.
Reasoning steps for option D
Why might pantothenate be considered?
Pantothenate forms coenzyme A, a key metabolic cofactor.
Why is pantothenate wrong?
Tryptophan is not its precursor, and it does not explain the aminoaciduria.
Takeaway: Hartnup disease can cause pellagra-like episodes because urinary and intestinal tryptophan loss limits niacin synthesis; protein support and nicotinamide address that link.
